Abstract
Treatment options for metastatic renal cell carcinoma (RCC) have been limited due to its resistance to chemotherapy and radiotherapy. Benefits from immunotherapeutic agents provide only a small subset of patients. During the past decade major advances have been made toward understanding the molecular basis of RCC development. Such acquired knowledge has offered unique opportunities for the development of molecular targeting agents. These agents are predominately small molecules or monoclonal antibodies that exert their action through modulation of protein activity or inhibition of amplified signals directly implicated in disease mechanism. To date, some of newly molecular targeted agents have entered advanced phases of clinical development, received marketing authorization by regulatory agencies and have opened a possibility of multiple treatment options. This article overviews current knowledge in RCC molecular pathology with recent clinical data, and discuss present strategies for future development of targeted therapies.
Keywords: Renal cell carcinoma, molecular targeting agents, hypoxia inducible factor, vascular endothelial growth factor, receptor tyrosine kinase inhibitors, sorafenib, sunitinib, temsirolimus
Current Pharmaceutical Design
Title: Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Volume: 14 Issue: 11
Author(s): Snezana K. Bjelogrlic, Sinisa Radulovic and Nada Babovic
Affiliation:
Keywords: Renal cell carcinoma, molecular targeting agents, hypoxia inducible factor, vascular endothelial growth factor, receptor tyrosine kinase inhibitors, sorafenib, sunitinib, temsirolimus
Abstract: Treatment options for metastatic renal cell carcinoma (RCC) have been limited due to its resistance to chemotherapy and radiotherapy. Benefits from immunotherapeutic agents provide only a small subset of patients. During the past decade major advances have been made toward understanding the molecular basis of RCC development. Such acquired knowledge has offered unique opportunities for the development of molecular targeting agents. These agents are predominately small molecules or monoclonal antibodies that exert their action through modulation of protein activity or inhibition of amplified signals directly implicated in disease mechanism. To date, some of newly molecular targeted agents have entered advanced phases of clinical development, received marketing authorization by regulatory agencies and have opened a possibility of multiple treatment options. This article overviews current knowledge in RCC molecular pathology with recent clinical data, and discuss present strategies for future development of targeted therapies.
Export Options
About this article
Cite this article as:
Bjelogrlic K. Snezana, Radulovic Sinisa and Babovic Nada, Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives, Current Pharmaceutical Design 2008; 14 (11) . https://dx.doi.org/10.2174/138161208784246252
DOI https://dx.doi.org/10.2174/138161208784246252 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Oncologists Current Opinion on the Treatment of Colon Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Natural Products: Potential for Developing Phellodendron amurense Bark Extract for Prostate Cancer Management
Mini-Reviews in Medicinal Chemistry Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Hypertension, Anti-Hypertensive Therapy and Neoplasia
Current Pharmaceutical Design Targeting Basal-Like Breast Cancers
Current Drug Targets Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Transposon-Based Engineering of Clinical-Grade T Cells for Cancer Therapy
Current Drug Therapy Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Nanoparticle Interaction with Biomolecules: How it Shapes the Nano-Effects on Immunity
Current Bionanotechnology (Discontinued) A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Current Cancer Drug Targets